Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.
More comprehensive research will be needed to further investigate cerebrospinal fluid p24 by high-sensitivity assay as a marker for neurocognitive impairment during poorly controlled HIV and as a marker for HIV central nervous system reactivation during latency reversal therapy.
Interventions for diabetes prevention and management may be needed to reduce the risk for diabetes in patients with HIV.
About half of pregnant women with HIV infection underwent cesarean delivery between 1998 and 2013.
Researchers assessed the differential risk of acquiring HIV-1 infection across reproductive stages by calculating per-coital-act risk for each stage and comparing with nonpregnant times.
Investigators assessed adherence to antiretroviral therapy, retention in care, and virologic outcomes in patients receiving once-daily single-tablet and multiple-tablet antiretroviral therapy regimens.
The effects of a peer navigation intervention on HIV viral suppression in previously incarcerated individuals were examined.
A head-to-head comparison was made between HIV-1 treatment regimens containing tenofovir alafenamide plus emtricitabine with those containing abacavir plus lamivudine.
Text messaging may be a promising strategy for support and engagement in HIV care.
Investigators sought to determine the association between antiretroviral therapy and cytomegalovirus infection in individuals with HIV, as well as the potential impact of both on neurocognitive performance.
Transcutaneous vagus nerve stimulation could provide a safe alternative treatment in HIV-depression by targeting both depression and other comorbidities that can burden people living with HIV.
Experts discuss new findings supporting the need for PrEP in adolescents and discuss the continued debate surrounding parental consent and other relevant issues.
The incidence of neurocognitive impairment is high in HIV-infected population, despite the introduction of combination antiretroviral therapy (CART).
Learn more about when stopping antiretroviral therapy (ART) may be necessary, why patients discontinue ART, predicting viral suppression, and predicting and encouraging adherence.
In addition to prevention measures, switching off the ARTs associated with bone loss and administering intravenous bisphosphonate, a bone resorption inhibitor, can be an effective strategy for preventing bone loss seen in HIV-infected individuals.
Three HIV experts provide their insights into aging-related challenges and complications faced by people living with HIV.
Several technological advances have been developed to improve adherence to antiretroviral and preexposure prophylaxis therapy.
Dr Sara Gianella Weibel talks with Anthony B, a patient with HIV and end-stage amyotrophic lateral sclerosis and the first participant enrolled in the "Last Gift" end-of-life study, about his experience as part of this new end-of-life model to study HIV persistence.
Dr Sara Gianella Weibel talks with Jeff Taylor, community activist and long-term HIV survivor, about a new end-of-life model to study HIV persistence.
Dr Sara Gianella Weibel talks with Dr Davey Smith, head of the Division of Infectious Disease at the University of California, San Diego, about a proposed new model to study HIV persistence, called the Last Gift study.
SIGN UP FOR FREE E-NEWSLETTERS
Infectious Disease Advisor Articles
- Generic HIV Medicines: Boon or Bust?
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- It Costs $2.2 Billion a Year to Treat Antibiotic Resistance
- Pregnancy May Be Independently Associated With Prolonged Detection of Zika Virus RNA
- Tricyclic Antidepressants May Reduce Cirrhosis Risk in Hepatitis C
- Clostridium difficile Infection in the Intensive Care Setting
- Combating Medically Important Antibiotic Use in Food-Producing Animals
- Religious Exemptions vs Mandatory Vaccinations: An Expert Perspective
- 2018 Vaccination Schedule: Adults
- Fingerstick Point-of-Care Test Allows for Single-Visit HCV Diagnoses
- Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection
- Fluoroquinolone Use May Increase Risk for Aortic Aneurysm and Dissection
- Reduced Risk of Hepatocellular Carcinoma in DAA-Treated HCV Infection
- Paracetamol Overuse During Cold and Flu Season
- C difficile Risk Higher With Stoma Reversal vs Colectomy